Forbes December 3, 2023
Bruce Y. Lee

Ileus is not a good gut feeling to have. And, the U.S. Food and Drug Administration (FDA) has added ileus—which can result in intestinal blockage—as a possible serious adverse event to the Ozempic label.

As a result, the Ozempic label has joined the labels of two other glucagon-like peptide-1 (GLP-1) receptor agonists, Mounjaro and Wegovy, that have already borne warnings about ileus. At least 20 people have reported experiencing blocked intestines to the FDA’s Adverse Events Reporting System (FAERS). There have also been two deaths reported as a result. All in all, the FDA has received over 8,500 reports of gastrointestinal disorders among those using medications that contain semaglutide the main active ingredient for Ozempic.

Now, 20 people may not...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
FDA issues flu vaccine recommendations: 5 respiratory updates
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns

Share This Article